Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2013-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2013.764409PMID 23350850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKε and TBK1 functions

  2013cited by this paper
• Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.

  2013cited by this paper
• An orally available, small-molecule interferon inhibits viral replication

  2012cited by this paper
• The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

  2012cited by this paper
• Interferon Alfacon-1

  2012cited by this paper
• Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses Type I Interferon Signaling

  2012influential reference
• Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α.

  2012influential reference
• Current progress in the treatment of chronic hepatitis C.

  2012cited by this paper
• Hepatitis C virus NS3/4A protease blocks IL‐28 production

  2012cited by this paper
• Interleukin-29 Suppresses Hepatitis A and C Viral Internal Ribosomal Entry Site-Mediated Translation

  2012cited by this paper
• Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies

  2012cited by this paper
• The Cell Biology of TRIM5α

  2012cited by this paper
• Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response

  2012cited by this paper
• IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population

  2012cited by this paper
• IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

  2011cited by this paper
• The Small Interferon-Induced Transmembrane Genes and Proteins

  2011influential reference
• Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy

  2011cited by this paper
• Pattern Recognition Receptors and the Innate Immune Response to Viral Infection

  2011influential reference
• Ribavirin Enhances IFN-α Signalling and MxA Expression: A Novel Immune Modulation Mechanism during Treatment of HCV

  2011cited by this paper
• Structural linkage between ligand discrimination and receptor activation by type I interferons.

  2011cited by this paper
• Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection.

  2011cited by this paper
• An overview of HCV molecular biology, replication and immune responses

  2011influential reference
• Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials

  2011cited by this paper
• Tetherin and Its Viral Antagonists

  2011influential reference
• The ISG56/IFIT1 Gene Family

  2011cited by this paper
• Viperin: a multifunctional, interferon-inducible protein that regulates virus replication.

  2011influential reference
• Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population

  2011influential reference
• Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

  2011cited by this paper
• In Vitro Sensitivity of Human Metapneumovirus to Type I Interferons

  2011cited by this paper
• Pandemic 2009 H1N1 Influenza Virus Is Resistant to the Antiviral Activity of Several Interferon Alpha Subtypes

  2011cited by this paper
• Interferons and MicroRNAs

  2010influential reference
• Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

  2010influential reference
• Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

  2010influential reference
• Factors determining effectiveness of interferons in managing hepatitis C: new targets and new approaches

  2010cited by this paper
• Intracellular DNA recognition

  2010cited by this paper
• Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha

  2010cited by this paper
• IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C

  2010cited by this paper
• Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

  2010cited by this paper
• Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C

  2010cited by this paper
• Comparative Analysis of the Lambda-Interferons IL-28A and IL-29 regarding Their Transcriptome and Their Antiviral Properties against Hepatitis C Virus

  2010influential reference
• Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A.

  2010cited by this paper
• Hepatitis C Virus Core Protein Abrogates the DDX3 Function That Enhances IPS-1-Mediated IFN–Beta Induction

  2010cited by this paper
• Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C

  2009cited by this paper
• Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

  2009cited by this paper
• Enhanced anti-HCV activity of interferon alpha 17 subtype

  2009cited by this paper
• Expert opinion on the treatment of patients with chronic hepatitis C

  2009cited by this paper
• Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

  2009cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors

  2009cited by this paper
• IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo

  2008cited by this paper
• Biological basis for a proper clinical application of alpha interferons.

  2008influential reference
• INTERFEROME: the database of interferon regulated genes

  2008influential reference
• Interferon signaling and treatment outcome in chronic hepatitis C

  2008cited by this paper
• Interferon-inducible antiviral effectors

  2008influential reference
• Novel Controlled-Release Lemna-Derived IFN-α2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial

  2008influential reference
• Differential receptor subunit affinities of type I interferons govern differential signal activation.

  2007cited by this paper
• MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment.

  2007cited by this paper
• MxA Induction May Predict Sustained Virologic Responses of Chronic Hepatitis B Patients with IFN-α Treatment

  2007cited by this paper
• Expression of biomarkers of interferon type I in patients suffering from chronic diseases

  2007influential reference
• Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.

  2007cited by this paper
• Pharmacodynamics of peginterferon alfa‐2a and peginterferon alfa‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study

  2007cited by this paper
• Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines

  2007cited by this paper
• Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors.

  2006cited by this paper
• Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.

  2006cited by this paper
• Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics

  2006cited by this paper
• Inquiring into the Differential Action of Interferons (IFNs): an IFN-α2 Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN-β

  2006cited by this paper
• Lambda Interferon (IFN-λ), a Type III IFN, Is Induced by Viruses and IFNs and Displays Potent Antiviral Activity against Select Virus Infections In Vivo

  2006influential reference
• Type I Interferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors (DOI:10.1016/j.immuni.2006.08.009)

  2006cited by this paper
• Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication.

  2006cited by this paper
• Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors

  2006cited by this paper
• Is interferon-beta an alternative treatment for chronic hepatitis C?

  2006cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

  2006cited by this paper
• Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon.

  2006cited by this paper
• Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy

  2005cited by this paper
• Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.

  2005influential reference
• Production of type I interferons

  2005influential reference
• Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

  2005cited by this paper
• Pegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT Pathway

  2004cited by this paper
• Interferon-gamma: an overview of signals, mechanisms and functions.

  2004influential reference
• MxA and PKR Expression in Chronic Hepatitis C

  2004cited by this paper
• Successful Long-term Application of Highly Purified Natural Interferon-alpha (Multiferon®) after Preceding Interferon Approaches in a Chronic Hepatitis C Patient with Thrombocytopenia

  2004cited by this paper
• Interferon- : an overview of signals, mechanisms and functions

  2004cited by this paper
• Interferons, interferon‐like cytokines, and their receptors

  2004influential reference
• ISG15, not just another ubiquitin-like protein.

  2003cited by this paper
• Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia

  2003influential reference
• ISG20, a New Interferon-induced RNase Specific for Single-stranded RNA, Defines an Alternative Antiviral Pathway against RNA Genomic Viruses*

  2003cited by this paper
• IL-28, IL-29 and their class II cytokine receptor IL-28R

  2002cited by this paper
• Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

  2002cited by this paper
• Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

  2002cited by this paper
• Different antiviral activities of IFN-α subtypes in human liver cell lines: synergism between IFN-α2 and IFN-α8

  2002cited by this paper
• Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8.

  2002cited by this paper
• Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

  2001cited by this paper
• Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

  2001cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Alpha-2b Formulations Administered Intramuscularly in Healthy Male Volunteers

  2000cited by this paper
• Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha Therapy

  1999cited by this paper
• Development of antibodies to interferon beta in patients: technical and biological aspects.

  1999cited by this paper
• The IFN gamma receptor: a paradigm for cytokine receptor signaling.

  1997influential reference

• Response regression model as a guiding principle for pharmacological mechanistic investigation of host-targeted antivirals

  2025cites this paper
• Blocking virus infection with BacMam virus delivery bovine interferon-α gene

  2024cites this paper
• Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action

  2023cites this paper
• Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy

  2021cites this paper
• Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral‐ or bacterial‐oriented immune responses

  2020cites this paper
• Immune Abnormalities in Autism Spectrum Disorder—Could They Hold Promise for Causative Treatment?

  2018cites this paper
• Type I/II Interferon in HIV-1-Infected Patients: Expression in Gut Mucosa and in Peripheral Blood Mononuclear Cells and Its Modification upon Probiotic Supplementation

  2018cites this paper
• Development of a promising interferon gene therapy strategy by vector design

  2018cites this paper
• Evaluation of antiviral effect of type I, II, and III interferons on direct‐acting antiviral‐resistant hepatitis C virus

  2017cites this paper
• Treatment of Delta Hepatitis: Today and in the Future - A review

  2017cites this paper
• Role of Interferons in Chronic Hepatitis C Infection.

  2017cites this paper
• Editorial: New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection and HCV Extrahepatic Manifestations.

  2017cites this paper
• Contact-dependent abrogation of bone marrow-derived plasmacytoid dendritic cell differentiation by murine mesenchymal stem cells.

  2016cites this paper
• IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection

  2016cites this paper
• Molecular Mediators: Cytokines

  2015cites this paper
• Expression and purification of Canis interferon α in Escherichia coli using different tags.

  2015cites this paper
• Mechanisms of Action of Antiviral Agents

  2015cites this paper
• Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women

  2014cites this paper
• Interferon lambda 1–3 expression in infants hospitalized for RSV or HRV associated bronchiolitis

  2014cites this paper
• Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use

  2014cites this paper
• Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients

  2014cites this paper
• IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS

  2014cites this paper
• Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1

  2013cites this paper
• Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors*

  2013cites this paper